cd38-specific antibodies  (GenScript corporation)

Journal: PLOS One

Article Title: CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity

doi: 10.1371/journal.pone.0321622

Figure Lengend Snippet: Immunocompromised NCG mice were inoculated with A , ANBL-6, B , LP-1, C , MM1.S, or D , JJN-3 tumor cells, at cell numbers outlined in the Materials and Methods section. When tumors reached an average volume of ~ 100 mm 3 (day 0), mice were randomized into treatment groups and treated via intraperitoneal injection with vehicle or 10 mg/kg hCD38-hAtt twice weekly for up to six doses. Tumor volumes were measured twice weekly until humane endpoint was reached. E, Tabulated data summary of CD38 and IFNAR2 expression (mean fluorescence intensity) of each tumor cell line, as measured by flow cytometry.

Article Snippet: Anti-murine CD38-murine Attenukine TM (mCD38-mAtt) was generated by cloning the mAtt fused to an anti-mouse CD38-specific antibody (generated internally at Takeda in a hybridoma campaign) into Expi293 cells (WuXi Biologics).

Techniques: Injection, Expressing, Fluorescence, Flow Cytometry

Journal: Arthritis Research & Therapy

Article Title: Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis

doi: 10.1186/s13075-023-03203-7

Figure Lengend Snippet: Expression of Bcl-2 family members in CD19+ B cell subsets ex vivo and after activation on day 6. Immunological detection of Bcl-2, Bcl-XL, and Mcl-1 expression in CD19+ naïve (N; CD27-/CD38-), memory B cells (Mem; CD27+/CD38-), and plasmablasts (PB; CD27+/CD38+) of healthy controls (HD; N = 13) compared to rheumatoid arthritis (RA; N = 12), and systemic lupus erythematosus (SLE; N = 14) ex vivo ( A–C ) and after stimulation with 1 µg/ml ODN2006 (CpG) for 6 days ( D–F ). Filled symbols represent active disease, open symbols remission. Data are expressed as mean ± SD

Article Snippet: PBMCs were stained with the antibodies specific for CD4 (Biolegend, San Diego, CA, USA), CD8 (Biolegend, San Diego, CA, USA), CD19 (BD Biosciences, San Jose, CA, USA), CD27 (BD Biosciences, San Jose, CA, USA), CD38 (BD Biosciences, San Jose, USA), CD45RA (BD Biosciences, San Jose, CA, USA), and IgD (Biolegend, San Diego, CA, USA).

Techniques: Expressing, Ex Vivo, Activation Assay

Journal: Arthritis Research & Therapy

Article Title: Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis

doi: 10.1186/s13075-023-03203-7

Figure Lengend Snippet: BH3 mimetics revealed that Mcl-1 inhibition was the most effective in reducing plasmablast viability after activation. PBMCs of healthy controls (HD; N = 3), rheumatoid arthritis (RA; N = 3), and systemic lupus erythematosus (SLE; N = 4) were stimulated with 1 µg/ml ODN2006 (CpG) for 6 days followed by in vitro treatment with the Bcl-2 inhibitor venetoclax (A–C), Mcl-1 inhibitor S63845 (D–F), or dual Bcl-2/Bcl-XL inhibitor AZD4320 (G–I) for 24 h. Viability data were measured by flow cytometry using DiOC6/TO-PRO-3 staining in CD19+ naïve (N; CD27-/CD38-), memory B cells (Mem; CD27+/CD38-), and plasmablasts (PB; CD27+/CD38+). Two-way Anova test was used for statistical analyses. * p < 0.05; ** p < 0.01; *** p < 0.001. Data are expressed as mean ± SEM

Article Snippet: PBMCs were stained with the antibodies specific for CD4 (Biolegend, San Diego, CA, USA), CD8 (Biolegend, San Diego, CA, USA), CD19 (BD Biosciences, San Jose, CA, USA), CD27 (BD Biosciences, San Jose, CA, USA), CD38 (BD Biosciences, San Jose, USA), CD45RA (BD Biosciences, San Jose, CA, USA), and IgD (Biolegend, San Diego, CA, USA).

Techniques: Inhibition, Activation Assay, In Vitro, Flow Cytometry, Staining